Trial Profile
A retrospective study assessing risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Therapeutic Use
- 11 May 2018 New trial record